The most recent guidelines recommend, for otitis externa antibiotic therapy, the use of topical formulations in that they are very safe, have a quicker effect and do not induce bacterial resistance compared to systemic therapy. The choice of the class of antibiotics in empiric therapy of otitis externa must take into consideration the polymicrobic nature ofthe infection that includes both bacteria (Grampositive and Gram-negative) and mycetes. For this reason, in this study we evaluated the synergic activity of neomycin in association with polymyxin B against the pathogens commonly responsible for otitis externa, compared to that of a single antibiotic (ciprofloxacin). The polymyxinB/neomycin association shows clear synergic effects with values of both Minimum Inhibitory Concentration (!\iIC) and Minimum Bactericidal Concentration (MBC) reduced by 3-4 times with respect to the single antibiotic; and in P. aeruginosa the synergistic effect of the neomycin/polymyxin B association with respect to neomycin was more evident (5-6 times), with an intrinsic in vitro activity constantly higher than that of ciprofloxacin alone or in association with hydrocortisone. From the analysis ofthe data obtained in vitro, we can conclude that the possibility of using a topical formulation containing a synergistic association of antibiotics, such as neomycin-polymyxin B, in such a way as to obtain the maximum effect in the minimum time with an increase in the spectrum of action of non-bacterial pathogens, is an optimal choice for the clinician for the empiric therapy of otitis externa.
Otitis externa is an inflammation of the outer ear canal and tympanic membrane, which has become one of the most frequent ENT pathologies. In most cases it is acute, sometimes associated with otitis media or infections of the upper respiratory tract and, in rare cases, there are severe complications (periauricular abscess, perichondritis) (1) . It is therefore important that the clinician obtains a rapid eradication of the pathogens responsible by means of a therapy based on cleansing the canal and administering antibiotics (oral or topical).
In its acute form, the etiology of otitis externa includes both bacteria (Gram-positive and Gram-negative) and mycetes; even if data in the international literature suggest that a principal role is played by Pseudomonas aeruginosa (30-50%), Staphylococcus aureus (10%) and Candida albicans (10%) (2) .
The therapeutic choice for otitis extema is, in most cases, empirical and must thus take into consideration the spectrum of actrvrty of the antibiotic against most of the pathogens involved; this is not always possible using a single antibiotic given the polymicrobic nature of the infection. For this reason, in this study we evaluated the synergistic activity of the neomycin-polymyxin B association: these are the active agents commonly used for the treatment of acute and chronic otitis extern a, with the addition oflidocaine, a local anesthetic (3) (4) .
Neomycin, an aminoglycosidic antibiotic, has a wide spectrum of action including Gram-positive cocci and bacilli (above all staphylococci) and Gramnegative bacteria (Enterobacter spp., Klebsiella spp., Serratia spp., P. aeruginosa and Proteus spp.).
Polymyxin B is a cyclic peptide, principally active against P. aeruginosa, Klebsiella spp., Enterobacter spp., Escherichia coli and Haemophilus influenzae. Its activity also extends to some fungal species such as Candida spp.
The association of neomycin with polymyxin B is thus active against all the bacteria commonly responsible for the various ENT forms of infection, in part~cular P. aeruginosa, S. aureus and Candida spp., principal etiological agents of otitis externa in children and adults.
MATERIALS AND METHODS
The evaluation of the synergistic activity of neomycin and polymyxin B, compared to ciprofloxacin, was carried out both in terms of intrinsic capacity Minimum Inhibitory Concentration (MIC) and Minimum Bactericidal Concentration (MBC) on all the strains examined, and in terms of bactericidal velocity against P aeruginosa and S. aureus, which are the pathogens principally responsible for otitis extema (5) . The eventual interference oflidocaine (with the neomycin/polymyxin B association; Anauran®) and hydrocortisone (with ciprofloxacin; Mediflox®) was also evaluated against in vitro anti-microbial activity.
Strains
The following 144 clinically isolated strains were tested: 64 Gram-positives (32 S. aureus, 6 S. epiderm idis, 2 S. xylosus, 2 S. hominis, 12 S. pneumoniae and 10 S. pyogenes) and 70 Gram-negatives (50 P aeruginosa, 8 E. coli and 12 K. pneumoniae), as well as 10 strains of Candida (C albicans, C parapsilosis and C krusei).
Control strains were: S. aureus ATCC 29213, E. coli ATCC 35218, E. coli ATCC 25922, P. aeruginosa ATCC 27853, S. pneumoniae ATCC 49619, S. pyogenes DSM All strains were seeded and purified in their respective culture media (MacConkey for the Gram-negatives, MSA for the staphylococci, CNA for the streptococci and Sabouraud for the mycetes).
The determination of the MIC, the MBC and the bactericidal curves for S. aureus and P aeruginosa were assayed for neomycin, polymyxin B, ciprofloxacin, as well as the "neomycin-polymyxin B-lidocaine" and "ciprofloxacin-hydrocortisone' associations. Table I shows the MIC and MBC values of the 144 strains of Gram-positive and Gram-negative bacteria studied. The neomycin/polymyxinB association shows clear synergistic effects with va lues of both MICs and MBCs reduced 3-4 times in respect to the single antibiotic and are comparable to, or less than, those obtained with ciprofloxacin. In particular (Table II) with regards to S. aureus, the neomycin/polymyxin B aSSOCIatIon had lower values (4 times) with MIC/MBC than those of the single components and were comparable to those of the ciprofloxacinlhydrocortisone association. This effect was demonstrated in most (neomycin) or all (pol ymyxin B) of the bacteria tested, consequently all the strains of S. aureus resi stant to at least one of the two components were sensitive to the association.
RESULTS
In P aeruginosa (Table II) the effect of the neomycin/polymyxin B association with respect to neomycin was more evident (5-6 times), with an intrinsic in vitro activity constantly higher than that of ciprofloxacin alone or in association with hydrocortisone. Finally, the anti-fungal activity of polymyxin B (Table III) was confirmed against all the strains of Candida tested, and we show that the association with neomycin caused, in some cases, a slight reduction in the MIC values. Obviously, ciprofloxacin had no anti-fungal activity. Figs. I and 2 show the results relative to the bactericidal curves. InS. aureus (Fig.  I) there is an overlap of the curve of the neomycin/ polymyxin B association with that of ciprofloxacin, with a reduction in the bacterial concentration after 2 h and a complete removal at 8 h. A better bactericidal effect of the association with respect to ciprofloxacin is, instead, already found in P. aeruginosa at 2 hand is still greater at 4 hand 8 h (Fig. 2) . It must also be said that from the observation of the bactericidal curve the synergic action between polymyxin Band neomycin is confirmed.
DISCUSSION
The most recent guidelines (6) recommend, for antibiotic therapy of the uncomplicated form of otitis extern a, the use of topical formulations in that they are very safe, have a quicker effect and do not induce bacterial resistance with respect to systemic therapy. Considering that, other than the bacterial component, also some species of Candida can be responsible, alone or in association with bacteria, for the onset of otitis externa, it thus follows that the therapeutic choice must be aimed at topical ear antibiotics with a wide spectrum of action, such as the neomycinpolymyxin B association, that, not only increases the antibacterial activity of the single components, but also extends, with respect to ciprofloxacin, the spectrum of action to mycetes.
These considerations have a valid theoretical support in the various mechanisms of action of the two agents: neomycin fixes at the level of the 30S subunit of the bacterial ribosome, inhibiting the exact incorporation of the aminoacids in the polypeptide chain, from which an incorrect protein synthesis derives. Polymyxin B, instead, fixes to the cytoplasmatic membrane of bacteria, altering its permeability, with the consequent loss of cellular constituents essential for the life of the organism.
The choice of the antibiotic class in empiric therapy of otitis externa must obviously take into consideration not only the spectrum of activity, but also the possibility of obtaining a bactericidal effect in as short a time as possible. The association of the antibiotic with hydrocortisone or analgesics, without interfering with the efficacy of the antibiotic, is useful for the possibility of obtaining a rapid resolution of the inflammatory process or pain. In our study we did not find any intrinsic anti-bacterial activity or interference effect of hydrocortisone and lidocaine.
From the analysis ofthe data obtained in vitro, we can conclude that the possibility of using a topical formulation containing a synergistic association of antibiotics, such as neomycin-polymyxin B, in such a way as to obtain the maximum effect in the minimum time with an increase in the spectrum of action of non-bacterial pathogens, is an optimal choice for the clinician for the empiric therapy of otitis extema.
